AVNS Quote, Financials, Valuation and Earnings

Edwards Lifesciences Corp. has a net margin of -0.72% compared to Avanos Medical, Inc.'s net margin of 4.09%. Avanos Medical, Inc.'s return on equity of -9.11% beat Edwards Lifesciences Corp.'s return on equity of 10.27%.

Avanos Medical, Inc. has a consensus price target of $14.00, signalling upside risk potential of 0.14%. On the other hand Edwards Lifesciences Corp. has an analysts' consensus of $96.46 which suggests that it could grow by 11.56%. Given that Edwards Lifesciences Corp. has higher upside potential than Avanos Medical, Inc., analysts believe Edwards Lifesciences Corp. is more attractive than Avanos Medical, Inc..

Avanos Medical, Inc. has a beta of 1.070, which suggesting that the stock is 7% more volatile than S&P 500. In comparison Edwards Lifesciences Corp. has a beta of 0.927, suggesting its less volatile than the S&P 500 by 7.349%.

Avanos Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edwards Lifesciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avanos Medical, Inc. pays -- of its earnings as a dividend. Edwards Lifesciences Corp. pays out -- of its earnings as a dividend.

Avanos Medical, Inc. quarterly revenues are $180.9M, which are smaller than Edwards Lifesciences Corp. quarterly revenues of $1.6B. Avanos Medical, Inc.'s net income of -$1.3M is lower than Edwards Lifesciences Corp.'s net income of $64.2M. Notably, Avanos Medical, Inc.'s price-to-earnings ratio is 45.94x while Edwards Lifesciences Corp.'s PE ratio is 47.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avanos Medical, Inc. is 0.93x versus 8.35x for Edwards Lifesciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband, Inc. has a net margin of -0.72% compared to Avanos Medical, Inc.'s net margin of -1118.87%. Avanos Medical, Inc.'s return on equity of -9.11% beat Nutriband, Inc.'s return on equity of -164.64%.

Avanos Medical, Inc. has a consensus price target of $14.00, signalling upside risk potential of 0.14%. On the other hand Nutriband, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 237.84%. Given that Nutriband, Inc. has higher upside potential than Avanos Medical, Inc., analysts believe Nutriband, Inc. is more attractive than Avanos Medical, Inc..

Avanos Medical, Inc. has a beta of 1.070, which suggesting that the stock is 7% more volatile than S&P 500. In comparison Nutriband, Inc. has a beta of 1.801, suggesting its more volatile than the S&P 500 by 80.088%.

Avanos Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avanos Medical, Inc. pays -- of its earnings as a dividend. Nutriband, Inc. pays out -- of its earnings as a dividend.

Avanos Medical, Inc. quarterly revenues are $180.9M, which are larger than Nutriband, Inc. quarterly revenues of $346.1K. Avanos Medical, Inc.'s net income of -$1.3M is higher than Nutriband, Inc.'s net income of -$3.9M. Notably, Avanos Medical, Inc.'s price-to-earnings ratio is 45.94x while Nutriband, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avanos Medical, Inc. is 0.93x versus 22.16x for Nutriband, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

PetVivo Holdings, Inc. has a net margin of -0.72% compared to Avanos Medical, Inc.'s net margin of -765.99%. Avanos Medical, Inc.'s return on equity of -9.11% beat PetVivo Holdings, Inc.'s return on equity of -335.08%.

Avanos Medical, Inc. has a consensus price target of $14.00, signalling upside risk potential of 0.14%. On the other hand PetVivo Holdings, Inc. has an analysts' consensus of -- which suggests that it could grow by 541.03%. Given that PetVivo Holdings, Inc. has higher upside potential than Avanos Medical, Inc., analysts believe PetVivo Holdings, Inc. is more attractive than Avanos Medical, Inc..

Avanos Medical, Inc. has a beta of 1.070, which suggesting that the stock is 7% more volatile than S&P 500. In comparison PetVivo Holdings, Inc. has a beta of 0.356, suggesting its less volatile than the S&P 500 by 64.425%.

Avanos Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PetVivo Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avanos Medical, Inc. pays -- of its earnings as a dividend. PetVivo Holdings, Inc. pays out -- of its earnings as a dividend.

Avanos Medical, Inc. quarterly revenues are $180.9M, which are larger than PetVivo Holdings, Inc. quarterly revenues of $286.1K. Avanos Medical, Inc.'s net income of -$1.3M is higher than PetVivo Holdings, Inc.'s net income of -$2.2M. Notably, Avanos Medical, Inc.'s price-to-earnings ratio is 45.94x while PetVivo Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avanos Medical, Inc. is 0.93x versus 19.25x for PetVivo Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings, Inc. has a net margin of -0.72% compared to Avanos Medical, Inc.'s net margin of 6.15%. Avanos Medical, Inc.'s return on equity of -9.11% beat Zimmer Biomet Holdings, Inc.'s return on equity of 5.61%.

Avanos Medical, Inc. has a consensus price target of $14.00, signalling upside risk potential of 0.14%. On the other hand Zimmer Biomet Holdings, Inc. has an analysts' consensus of $102.65 which suggests that it could grow by 4.28%. Given that Zimmer Biomet Holdings, Inc. has higher upside potential than Avanos Medical, Inc., analysts believe Zimmer Biomet Holdings, Inc. is more attractive than Avanos Medical, Inc..

Avanos Medical, Inc. has a beta of 1.070, which suggesting that the stock is 7% more volatile than S&P 500. In comparison Zimmer Biomet Holdings, Inc. has a beta of 0.585, suggesting its less volatile than the S&P 500 by 41.541%.

Avanos Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zimmer Biomet Holdings, Inc. offers a yield of 0.98% to investors and pays a quarterly dividend of $0.24 per share. Avanos Medical, Inc. pays -- of its earnings as a dividend. Zimmer Biomet Holdings, Inc. pays out 27.05% of its earnings as a dividend. Zimmer Biomet Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Avanos Medical, Inc. quarterly revenues are $180.9M, which are smaller than Zimmer Biomet Holdings, Inc. quarterly revenues of $2.2B. Avanos Medical, Inc.'s net income of -$1.3M is lower than Zimmer Biomet Holdings, Inc.'s net income of $137.9M. Notably, Avanos Medical, Inc.'s price-to-earnings ratio is 45.94x while Zimmer Biomet Holdings, Inc.'s PE ratio is 27.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avanos Medical, Inc. is 0.93x versus 2.38x for Zimmer Biomet Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.